IL17A and psoriasis: Several mAbs (secukinumab, ixekizumab, bimekizumab, brodalumab, risankizumab, trldrakizumab and guselkumab) that target IL-17, IL-23 and IL-17RA have proven efficacious in the treatment of psoriasis [122].